KR101841304B1 - 치료학적 치료를 제공하기 위한 방법, 조성물 및 키트 - Google Patents

치료학적 치료를 제공하기 위한 방법, 조성물 및 키트 Download PDF

Info

Publication number
KR101841304B1
KR101841304B1 KR1020127030962A KR20127030962A KR101841304B1 KR 101841304 B1 KR101841304 B1 KR 101841304B1 KR 1020127030962 A KR1020127030962 A KR 1020127030962A KR 20127030962 A KR20127030962 A KR 20127030962A KR 101841304 B1 KR101841304 B1 KR 101841304B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
treatment
biochemical
thyroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127030962A
Other languages
English (en)
Korean (ko)
Other versions
KR20130103336A (ko
Inventor
오스나트 에슈어-파비안
알레크 헤르크베르그스
Original Assignee
오스나트 에슈어-파비안
알레크 헤르크베르그스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오스나트 에슈어-파비안, 알레크 헤르크베르그스 filed Critical 오스나트 에슈어-파비안
Publication of KR20130103336A publication Critical patent/KR20130103336A/ko
Application granted granted Critical
Publication of KR101841304B1 publication Critical patent/KR101841304B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127030962A 2010-04-28 2011-04-28 치료학적 치료를 제공하기 위한 방법, 조성물 및 키트 Expired - Fee Related KR101841304B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32882510P 2010-04-28 2010-04-28
US61/328,825 2010-04-28
PCT/IL2011/000346 WO2011135574A1 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Publications (2)

Publication Number Publication Date
KR20130103336A KR20130103336A (ko) 2013-09-23
KR101841304B1 true KR101841304B1 (ko) 2018-03-22

Family

ID=44860959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127030962A Expired - Fee Related KR101841304B1 (ko) 2010-04-28 2011-04-28 치료학적 치료를 제공하기 위한 방법, 조성물 및 키트

Country Status (11)

Country Link
US (2) US9655984B2 (enExample)
EP (1) EP2563120B1 (enExample)
JP (1) JP5921529B2 (enExample)
KR (1) KR101841304B1 (enExample)
CN (1) CN102858156B (enExample)
AU (1) AU2011246851B2 (enExample)
BR (1) BR112012027463A2 (enExample)
CA (1) CA2797625C (enExample)
ES (1) ES2791708T3 (enExample)
MX (1) MX2012012479A (enExample)
WO (1) WO2011135574A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
US20200222348A1 (en) * 2017-05-08 2020-07-16 Musli Thyropeutics Ltd. Bimodal modified release compositions for cancer treatment
WO2021257806A1 (en) * 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome
CN114605278A (zh) * 2022-02-11 2022-06-10 天津市肿瘤医院（天津医科大学肿瘤医院） T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用
CN114878840A (zh) * 2022-07-12 2022-08-09 昆明思安生物科技有限公司 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851610A (en) 1956-03-07 1960-10-19 Gunther Hillman Method for producing iodine derivatives of thyronine
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6939863B2 (en) * 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
JP2009507847A (ja) * 2005-09-08 2009-02-26 シャイア エルエルシー 生体利用性を増強したｔ３及びｔ４のプロドラッグ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anticancer Research 23:617-626(2003)
Int. J. Radiation Oncology Biol. Phys. 1:645-650(1976)
Veterinary Medicine(2001)

Also Published As

Publication number Publication date
AU2011246851A1 (en) 2012-11-15
MX2012012479A (es) 2013-07-03
EP2563120A4 (en) 2015-05-13
BR112012027463A2 (pt) 2015-09-29
EP2563120A1 (en) 2013-03-06
US20170274104A1 (en) 2017-09-28
EP2563120B1 (en) 2020-02-26
JP5921529B2 (ja) 2016-05-24
CA2797625A1 (en) 2011-11-03
US10398789B2 (en) 2019-09-03
AU2011246851B2 (en) 2016-07-21
KR20130103336A (ko) 2013-09-23
JP2013525422A (ja) 2013-06-20
US9655984B2 (en) 2017-05-23
ES2791708T3 (es) 2020-11-05
US20130129615A1 (en) 2013-05-23
CA2797625C (en) 2019-08-20
CN102858156B (zh) 2015-09-23
WO2011135574A1 (en) 2011-11-03
CN102858156A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
US10398789B2 (en) Methods, compositions and kits for providing a therapeutic treatment
ES2985986T3 (es) Conjugado biciclo para tratar el cáncer
O'Rawe et al. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial
JP7169297B2 (ja) 再発膠芽腫（ｒｇｂｍ）の治療方法
ES2881928T3 (es) Profármacos de etopósido para su uso en el direccionamiento a las células madre cancerosas
Wang et al. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC
Chen et al. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts
KR101747775B1 (ko) 유포비아 인자 l1 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물
KR20170104114A (ko) 암을 치료하기 위한 조성물과 방법
TW201728334A (zh) 用於治療癌症之組合物及方法
KR100954625B1 (ko) 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
CN107569485A (zh) 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂
TW202423403A (zh) 一種治療前列腺癌的藥物組合及其應用
CN114010653B (zh) 包括人参皂苷Rg1和岩藻多糖的组合物在制备降低组织因子的表达的药物中的应用
CN104840459B (zh) 17‑丙烯胺‑17‑去甲氧格尔德霉素在制备治疗癫痫的药物中的用途
JP2015505313A (ja) 癌を治療するための併用療法
CN108503676A (zh) 用于癌症治疗的果糖类似物及其组合物
EP3515443B1 (en) Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivative as a vda and a topoisomerase inhibitor
WO2012116975A1 (en) Method for administration of a gamma secretase inhibitor
KR20230034179A (ko) 피콜리나펜을 유효성분으로 포함하는 혈관신생 억제용 약학적 조성물
KR101668105B1 (ko) miR-770-5p를 유효성분으로 포함하는 방사선 민감성 증진용 조성물
CN119698276A (zh) 用酰基富烯与依鲁替尼或硼替佐米的组合治疗癌症
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK1220365B (en) Etoposide prodrugs for use in targeting cancer stem cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210317

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210317